Next-Generation Factor XIa Cuts Recurrent Stroke Risk by 26%

(MedPage Today) — NEW ORLEANS — Factor XIa (FXIa) inhibition for secondary stroke prevention got a major win in the large OCEANIC-STROKE placebo-controlled trial.
Among adults with acute non-cardioembolic ischemic stroke or high-risk transient…

Source link : https://www.medpagetoday.com/meetingcoverage/isc/119756

Author :

Publish date : 2026-02-05 20:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Next-Generation Factor XIa Cuts Recurrent Stroke Risk by 26%

Bonobo’s pretend tea party shows capacity for imagination

Hims & Hers Launches Copy of Wegovy Pill, Prompting Legal Threats

Related Posts

Inhaled Vasodilator Slows Lung Function Decline in Idiopathic Pulmonary Fibrosis

Goodbye FAERS? FDA Launches New Combined Adverse Event Database

Lead Suits Cut Physician Radiation Exposure for Interventional Cardiology Cases

Traditional Medicare Enrollees Paid Billions More in Premiums Due to MA Overpayments

FDA Warns GLP-1 Maker Over Failure to Properly Report Deaths, Strokes

Apixaban Snags a Win in Head-to-Head Trial of Direct Oral Anticoagulants

Inhaled Vasodilator Slows Lung Function Decline in Idiopathic Pulmonary Fibrosis

Goodbye FAERS? FDA Launches New Combined Adverse Event Database

Lead Suits Cut Physician Radiation Exposure for Interventional Cardiology Cases

Traditional Medicare Enrollees Paid Billions More in Premiums Due to MA Overpayments

FDA Warns GLP-1 Maker Over Failure to Properly Report Deaths, Strokes

Apixaban Snags a Win in Head-to-Head Trial of Direct Oral Anticoagulants

Drug Cuts Treatment Modifications From Chemotherapy-Induced Thrombocytopenia

GLP-1 Drugs May Benefit Cancer Patients With Brain Lesions

Categories

Archives